DOCSLIB.ORG

Topical Antifungal Composition Topische Antimykotische Zusammensetzung Composition Antifongique Topique

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Topical Antifungal Composition Topische Antimykotische Zusammensetzung Composition Antifongique Topique (19) TZZ __T (11) EP 2 451 468 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 36/53 (2006.01) A61K 36/534 (2006.01) 11.01.2017 Bulletin 2017/02 A61K 36/14 (2006.01) A61K 36/15 (2006.01) A61K 36/23 (2006.01) A61K 36/235 (2006.01) (2006.01) (2006.01) (21) Application number: 10731892.5 A61K 36/54 A61K 36/61 A61K 31/045 (2006.01) A61K 31/05 (2006.01) A61P 31/00 (2006.01) (22) Date of filing: 06.07.2010 (86) International application number: PCT/US2010/041050 (87) International publication number: WO 2011/005749 (13.01.2011 Gazette 2011/02) (54) TOPICAL ANTIFUNGAL COMPOSITION TOPISCHE ANTIMYKOTISCHE ZUSAMMENSETZUNG COMPOSITION ANTIFONGIQUE TOPIQUE (84) Designated Contracting States: (56) References cited: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB WO-A1-2005/087244 WO-A2-96/37210 GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO WO-A2-2004/076680 PL PT RO SE SI SK SM TR • DALLEAU S ET AL: "In vitro activity of essential (30) Priority: 08.07.2009 US 223870 P oils and their major components against Candida albicans yeasts growing planktonically and as (43) Date of publication of application: biofilms" INTERNATIONAL JOURNAL OF 16.05.2012 Bulletin 2012/20 ANTIMICROBIAL AGENTS, vol. 29, no. Suppl. 2, March 2007 (2007-03), page S147, XP22037821 & (73) Proprietor: Onikolabs LLC 17TH EUROPEAN CONGRESS OF CLINICAL Cincinnati, OH 45249-1211 (US) MICROBIOLOGY AND INFECTIOUS DISEASES/25TH INTERNATIONAL CONGRESS; (72) Inventor: BOEGLI, Charles, J. MUNICH, GERMANY; MARCH 31 -APRIL 03, 2007 Cincinnati ISSN: 0924-8579 OH 45249-1211 (US) • KALEMBA D ET AL: "ANTIBACTERIAL AND ANTIFUNGAL PROPERTIES OF ESSENTIAL (74) Representative: Samson & Partner Patentanwälte OILS" CURRENT MEDICINAL CHEMISTRY, mbB BENTHAMSCIENCE PUBLISHERS BV, BE LNKD- Widenmayerstraße 6 DOI:10.2174/0929867033457719, vol. 10, no. 10, 1 80538 München (DE) January 2003 (2003-01-01), pages 813-829, XP008056360 ISSN: 0929-8673 Remarks: Thefile contains technical information submitted after the application was filed and not included in this specification Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). EP 2 451 468 B1 Printed by Jouve, 75001 PARIS (FR) EP 2 451 468 B1 Description BACKGROUND OF THE INVENTION 5 [0001] Many of the commonly used antimicrobial agents are synthetic compounds. In recent years, there has been an increased interest in avoiding or eliminating the use of synthetic compounds and in developing and promoting the use of natural materials. Consumers generally consider plant materials less toxic and a more suitable natural alternative to synthetic compounds. [0002] Various herbal and plant preparations are known for certain uses. For example, Listerine® antiseptic mouthwash 10 is a known composition containing thyme oil, eucalyptus oil, methyl salicylate (wintergreen oil), and menthol in an alcohol solution. This composition is produced as an oral hygiene composition. Various reports have been produced showing Listerine® causes a reduction in plaque and gingivitis. Although various other plant compositions have been produced, many of the commercially available compositions have not shown substantial antimicrobial activity. [0003] The body normally serves as host for a variety of bacteria and fungi. Most of the time, the balance between 15 the body as host and the microorganisms is maintained. Sometimes, however, conditions exist that permit the microor- ganisms to tip that balance, causing an infection. Such fungi are only problematic when they grow in an uncontrolled manner, causing various diseases as well as discomfort for the infected human or animal. Unfortunately, uncontrolled fungal growths regularly occur, making topical anti-fungal preparations one of the largest segments of the market for topical external products. 20 [0004] Once fungal populations have become uncontrolled, the resultant infection is difficult to treat successfully. Synthetic topical antifungal preparations are commonly used for treatment. However, such infections are often recurrent and require a prolonged treatment regimen. Some consumers find prolonged treatment using synthetic products unde- sirable. [0005] Certain fungal infections of the skin known as tinea infections are caused by dermatophytes, which are members 25 of the Trichophyton, Microsporum and Epidermophyton species. These mold-like fungi thrive in warm, moist areas, thriving on the dead tissues of hair, nails, and outer skin layers. Tinea infections include tinea pedis, known as athlete’s foot; tinea corporis, known as ringworm; tinea capitis, a fungal infection of the scalp that can cause hair loss; tinea cruris, known as jock itch or tinea of the groin; tinea unguum, which is tinea of the nails; and tinea versicolor, a superficial fungal infection that produces brown, tan, or white spots on the trunk of the body. Tinea infections are contagious and can be 30 passed through direct contact or by contact with clothing, from shower and pool surfaces, and even from pets. [0006] Athlete’s foot or tinea pedis is by far the most common form, with more than 12 million people in the United States suffering from the disease per year. It presents with redness, itching, burning, cracking, scaling, swelling and occasionally bleeding. The condition generally includes small vesicles, fissures, scaling, maceration, hyperkeratinization, and eroded areas between the toes and on the plantar surface of the foot, as well as on other skin areas. The nails may 35 show thickening, pitting and subungal debris. Local antifungals include imidazoles, such as miconazole nitrate and clotrimazole, tolnaftate, and terbinafine hydrochloride. The common fungicidal and fungistatic chemical treatments fre- quently fail to contact the fungi in the horny layers of the skin, which means athlete’s foot slowly clears with local antifung al therapy or systemic antifungals. This requires the infected individual to take treatments for considerable lengths of time, potentially for months. Common treatments for athlete’s foot using local antifungals require treatment two or three times 40 a day for at least 7 to 14 days, and for some medications, for up to four weeks. It is common treatment to apply the topical antifungal for two weeks after the skin is healed, to eradicate all remaining fungal spores. Physicians commonly prescribe medications in the form of powders, aerosols, liquids or creams for the treatment of tinea pedis. [0007] However, reoccurrences of the infection are frequent. For some patients, such as those also afflicted with diabetes or circulatory problems, tinea infections and their treatment can be quite serious. The source of the affliction 45 often is a public safety and health concern, as the occurrence of tinea pedis is higher in public areas such as locker rooms, public showers, sports facilities, and the like. [0008] Increasingly, herbal remedies are sought due to concerns caused by antibiotic-resistant and other drug-resistant infectious agents. Even with herbal treatments, however, numerous difficulties are encountered in the treatment of medical conditions. A single herb may contain numerous active, and sometimes conflicting, components. The common 50 herb, rhubarb, for example, may be used in small doses for treating constipation due to its tannic acid component, but is a potent laxative in larger doses because of other components. Other herbs, such as black walnut extract, which may be used to treat athlete’s foot and related fungal infections, can be toxic if taken inappropriately. In addition to those difficulties mentioned in connection with single herbs, combinations raise the possibility of deleterious effects among components in the various herbs, and increase the difficulties associated with anticipating and analyzing side effects. 55 WO 96/37210 discloses various preparations in which, among others, Origanum vulgaris oil in concentrations of from 3 to 5 or 6 % and Mentha piperita oil in concentrations of from 0.5 to 1.5 % are present. These preparations comprise at least 80% of a vehicle. 2 EP 2 451 468 B1 BRIEF SUMMARY OF THE INVENTION [0009] The present invention relates to an antimicrobial composition comprising at least 40 % of one or more phenolic compounds selected from carvacrol and thymol and at least 15 % menthol. 5 [0010] In an embodiment of the present invention, the one or more phenolic compounds are contained in origanum oil. [0011] The composition comprises one or more phenolic compounds, namely carvacrol or thymol, and a secondary alcohol, namely menthol. The composition comprises at least 40% of the one or more phenolic compounds. [0012] -The composition may comprise at most about 15%, or 20% of the secondary alcohol. [0013] -The composition may further comprises an additional antifungal agent selected from the group consisting of 10 miconazole, econazole, ketoconazole, itraconazole, fluconazole, bifoconazole, terconazole, butoconazole, tioconazole, oxiconazole, sulconazole, saperconazole, clotrimazole, isoconazole, butoconazole, clioquinol, lanoconazole, neticona- zole, ciclopirox, butenafine, undecylenic acid, haloprogin, tolnaftate, nystatin, ciclopirox olamine, terbinafine, amorolfine,
Load more

Recommended publications
  • Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2B Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis
    Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis -Interim Results Demonstrate Strong Clinical Benefit and Favorable Safety Profile- -Final Data Expected in Fourth Quarter of 2016- RESEARCH TRIANGLE PARK, N.C., March 9, 2016, – Viamet Pharmaceuticals, Inc. today reported positive results from a planned interim analysis of REVIVE (Recurrent Vulvovaginal Candidiasis Inhibition: an Oral VT-1161 Tablet Evaluation), its ongoing Phase 2b clinical trial of VT-1161 for the treatment of recurrent vulvovaginal candidiasis, or RVVC. RVVC is defined as three or more episodes of acute vulvovaginal candidiasis, or AVVC (commonly referred to as a vaginal yeast infection), in a 12-month period. VT-1161, the company’s lead product candidate, is a highly potent and selective, orally available inhibitor of fungal CYP51. “It is estimated that RVVC affects 5% to 8% of U.S. women during their child-bearing years and has a significant negative impact on quality of life,” commented Robert Schotzinger, M.D., Ph.D., CEO of Viamet. “Despite the number of women affected by this disease, we are not aware of any approved therapies for RVVC in the U.S. VT-1161 has demonstrated a high degree of potency against Candida species, the causative fungal pathogens responsible for RVVC, a robust oral pharmacokinetic profile, and a favorable safety profile in previous studies. These attributes, coupled with the positive interim results from our REVIVE trial, suggest that VT-1161 has the potential to be a highly effective treatment option for patients with RVVC.” REVIVE is a randomized, double-blind, placebo-controlled, 48-week clinical trial of VT-1161 in patients with RVVC.
    [Show full text]
  • Candida & Nutrition
    Candida & Nutrition Presented by: Pennina Yasharpour, RDN, LDN Registered Dietitian Dickinson College Kline Annex Email: [email protected] What is Candida? • Candida is a type of yeast • Most common cause of fungal infections worldwide Candida albicans • Most common species of candida • C. albicans is part of the normal flora of the mucous membranes of the respiratory, gastrointestinal and female genital tracts. • Causes infections Candidiasis • Overgrowth of candida can cause superficial infections • Commonly known as a “yeast infection” • Mouth, skin, stomach, urinary tract, and vagina • Oropharyngeal candidiasis (thrush) • Oral infections, called oral thrush, are more common in infants, older adults, and people with weakened immune systems • Vulvovaginal candidiasis (vaginal yeast infection) • About 75% of women will get a vaginal yeast infection during their lifetime Causes of Candidiasis • Humans naturally have small amounts of Candida that live in the mouth, stomach, and vagina and don't cause any infections. • Candidiasis occurs when there's an overgrowth of the fungus RISK FACTORS WEAKENED ASSOCIATED IMUMUNE SYSTEM FACTORS • HIV/AIDS (Immunosuppression) • Infants • Diabetes • Elderly • Corticosteroid use • Antibiotic use • Contraceptives • Increased estrogen levels Type 2 Diabetes – Glucose in vaginal secretions promote Yeast growth. (overgrowth) Treatment • Antifungal medications • Oral rinses and tablets, vaginal tablets and suppositories, and creams. • For vaginal yeast infections, medications that are available over the counter include creams and suppositories, such as miconazole (Monistat), ticonazole (Vagistat), and clotrimazole (Gyne-Lotrimin). • Your doctor may prescribe a pill, fluconazole (Diflucan). The Candida Diet • Avoid carbohydrates: Supporters believe that Candida thrives on simple sugars and recommend removing them, along with low-fiber carbohydrates (eg, white bread).
    [Show full text]
  • Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
    CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre,
    [Show full text]
  • Tepzz¥Z8 4A T
    (19) TZZ¥Z_ _ T (11) EP 3 081 214 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 19.10.2016 Bulletin 2016/42 A61K 31/4178 (2006.01) A61K 31/422 (2006.01) A61P 25/28 (2006.01) (21) Application number: 16000020.4 (22) Date of filing: 30.08.2004 (84) Designated Contracting States: • Yuan, Junying, AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Newton, HU IE IT LI LU MC NL PL PT RO SE SI SK TR MA 02468 (US) • Jagtap, Prakash, (30) Priority: 29.08.2003 US 498882 P North Andover, MA 01845 (US) (62) Document number(s) of the earlier application(s) in • Degterev, Alexei, accordance with Art. 76 EPC: Brookline, 10011481.8 / 2 384 753 MA 02445 (US) 04821344.1 / 1 663 184 (74) Representative: Bösl, Raphael Konrad (71) Applicants: Isenbruck Bösl Hörschler LLP • THE BRIGHAM AND WOMEN’S HOSPITAL, INC. Patentanwälte Boston, MA 02115 (US) Prinzregentenstraße 68 • President and Fellows of Harvard College 81675 München (DE) Cambridge, MA 02138 (US) Remarks: (72) Inventors: •This application was filed on 05-01-2016 as a • Cuny, Gregory D., divisional application to the application mentioned Houston, under INID code 62. TX 77004 (US) •Claims filed after the date of filing of the application (Rule 68(4) EPC). (54) INHIBITORS OF CELLULAR NECROSIS (57) The present invention relates to compounds and pharmaceutical preparations and their use in therapy for preventing or treating trauma, ischemia, stroke and degenerative diseases associated with cell death. Methods and compositions of the invention are particularly useful for treating neurological disorders associated with cellular necrosis.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Isoconazole (nitrate) Item No. 30100 CAS Registry No.: 24168-96-5 Cl Formal Name: 1-[2-(2,4-dichlorophenyl)-2-[(2,6- dichlorophenyl)methoxy]ethyl]-1H- imidazole, mononitrate Synonyms: Adestan G 100, R 15454 Cl Cl MF: C18H14Cl4N2O • HNO3 FW: 479.1 N N Purity: ≥98% O Supplied as: A solid Storage: -20°C • HNO3 Cl Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Isoconazole (nitrate) is supplied as a solid. A stock solution may be made by dissolving the isoconazole (nitrate) in the solvent of choice, which should be purged with an inert gas. Isoconazole (nitrate) is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of isoconazole (nitrate) in these solvents is approximately 10 mg/ml. Isoconazole (nitrate) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, isoconazole (nitrate) should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Isoconazole (nitrate) has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Description Isoconazole is an imidazole with antimicrobial activity.1 It is active against clinical isolates of Candida species, including C. albicans, C. parapsilosis, C. tropicalis, C. krusei, and C. guilliermondii with MIC values ranging from 0.12 to 2 μg/ml. It is also active against the fungi T. mentagrophytes and T. rubrum when used at a concentration of 0.1 µg/ml and the bacteria C.
    [Show full text]
  • Oral Thrush A
    Oral thrush A. Introduction Oral thrush occurs when a yeast infection develops on the inside of your mouth and on your tongue. This condition is also known as oral candidiasis, oropharyngeal candidiasis, or, simply, thrush. The Candida albicans (C. albicans) fungus causes oral thrush. Candida is a normal organism in your mouth, but sometimes it can overgrow and cause symptoms. Oral thrush most often occurs in infants and toddlers. Oral thrush is typically mild and rarely causes complications. However, the condition can be problematic for those with weakened immune systems. B. Signs and Symtoms Oral thrush is usually harmless. It's common in babies and older people with dentures. It can be easily treated with medicines bought from a pharmacy. Adults Your mouth is red inside and you have white patches When you wipe off the white patches, they leave red spots that can bleed Other symptoms in adults are: 1.cracks at the corners of the mouth 2.not tasting things properly 3.an unpleasant taste in the mouth 4.pain inside the mouth (for example, a sore tongue or sore gums) 5.difficulty eating and drinking Oral thrush in adults isn't contagious. Babies A white coating on the tongue like cottage cheese – this can't be rubbed off easily Sometimes there are white spots in their mout Other symptoms in babies are: 1.they don't want to feed 2.nappy rash Babies can pass oral thrush on through breastfeeding. This can cause nipple thrush in mothers. C. Treatment Treatment for oral thrush varies depending on your age and overall health.
    [Show full text]
  • Fungal Infection
    Fungal Infection What is a Fungus? A Fungus is a tiny microorganism that belongs to the eukaryotic group and is ubiquitous in nature. They can be found in the soil, plants, decaying organic matter, damp places, and also in humans and animals. They include yeast, moulds, mushrooms and several others out of which some are pathogenic to humans. What is Fungal Infection? Fungal infection, also known as mycosis, is a broad term to describe various disease conditions caused by different types of fungi. Sometimes, fungi that aren’t present in the normal flora can colonize and induce an infection. Or the disruption of normal flora can lead to a fungal infection. Fungal infections can affect anyone at any age. If it spreads, then the treatment and control of these infections become extremely challenging. What are the different types of Fungal Infections? There are several types of fungal infections that can cause serious damage to health. Some of the common types of fungal infections are as follows: Ringworm infections Nail infections Athlete’s foot Vaginal yeast infections Oral thrush Jock itch 1 Scalp infections, etc. The fungus can also cause a full-blown infection, sinus infections and deep lung infections. What are the signs and symptoms of different Fungal Infections? The signs and symptoms of different fungal infections widely vary from each other, and some of them are discussed below: Signs and symptoms of Ringworm infections- Formation of a red ring-like patch, development of blisters around the affected area, itching and burning sensation. Signs and symptoms of Nail infections- Discoloration of nails, destruction of their normal shape, brittle nails, a feeling of pain and pressure in the affected area.
    [Show full text]
  • TISSUE INJURY INDUCED by CANDIDA ALBICANS Menstrual Period Occurring on the 26Th Day of "She's More Active," "Doesn't Sit and Hold Her Treatment
    Tissue Injury Induced By Candida Albicans Mental and Neurologic Manifestations C. Orian Truss, M.D.I Introduction body complexes or the presence of "auto- Medical research of the past several decades antibodies" to one's own tissues are but two has greatly expanded our knowledge of the examples. deranged chemistry and physiology that The same "dead end" is reached, however, characterize many individual disease states. Yet when the search for a virus or other antigenic most diseases have stubbornly resisted the agent is unfruitful. The evidence indicates that massive effort to unlock the secret of their an immunologic response is taking place and etiologies. We learn more and more about the is in some way involved in the disease abnormalities of function that result in clinical process, but the antigenic agent continues to symptoms and signs, but continue to be frustrated elude discovery. in our effort to discover the identity of the factor Or we may postulate that the immunologic initiating the departure from normal function. It is process occurs secondary to toxic damage to a unfortunate that the list of such diseases is headed tissue, leading to autoantibodies and perhaps by those that are the most frequent cause of to antigen-antibody complex deposition. But disability and death. Among them would be again, such a toxin escapes detection, if it atherosclerosis, most often clinically expressed as exists. hypertension, heart attacks, and strokes; In presenting selected, cases treated during malignancies, "auto-immune" diseases, arthritis, the past 16 years, I hope to call attention to muscle-wasting diseases, mental and neurologic Candida Albicans as a possible candidate for disorders, and many others.
    [Show full text]
  • (Clotrimazole Vaginal Cream USP 1%) Clotrimaderm Vaginal 3
    PRODUCT MONOGRAPH Clotrimaderm Vaginal 6 (Clotrimazole Vaginal Cream USP 1%) Clotrimaderm Vaginal 3 (Clotrimazole Vaginal Cream USP 2%) Clotrimaderm External Cream (Clotrimazole Vaginal Cream USP 1%) Antifungal Agent Taro Pharmaceuticals Inc. Date of Preparation: 130 East Drive January 27, 2020 Brampton, Ontario L6T 1C1 Control #232921 Page 1 of 22 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 3 SUMMARY PRODUCT INFORMATION ...................................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................................... 3 CONTRAINDICATIONS ................................................................................................................. 3 WARNINGS AND PRECAUTIONS ............................................................................................... 3 ADVERSE REACTIONS ................................................................................................................. 4 DRUG INTERACTIONS .................................................................................................................. 5 DOSAGE AND ADMINISTRATION ............................................................................................. 5 OVERDOSAGE ................................................................................................................................. 6 ACTION AND CLINICAL PHARMACOLOGY ......................................................................
    [Show full text]
  • Dermatologic Medication in Pregnancy
    Marušić et al. Acta Dermatovenerol Croat Subcutaneous dirofilariasis Acta Dermatovenerol Croat 2009;17(1):40-47 REVIEW Dermatologic Medication in Pregnancy Petra Turčić1, Zrinka Bukvić Mokos2, Ružica Jurakić Tončić2, Vladimir Blagaić3, Jasna Lipozenčić2 1School of Pharmacy and Biochemistry, University of Zagreb; 2University Department of Dermatology and Venereology, Zagreb University Hospital Center and School of Medicine; 3University Department of Obstetrics and Gynecology, Sveti Duh General Hospital, Zagreb, Croatia Corresponding author: SUMMARY In female body, a vast number of skin changes occur Petra Turčić, Phar. M. during pregnancy. Some of them are quite distressing to many women. Department of Pharmacology Therefore, performing treatment for physiologic skin changes during pregnancy with antiinfective agents, glucocorticosteroids, topical School of Pharmacy and Biochemistry immunomodulators, retinoids, minoxidil, etc., is discussed. Drug University of Zagreb administration during pregnancy must be reasonable. Domagojeva 2 KEY WORDS: dermatologic medication, pregnancy, physiologic skin HR-10000 Zagreb changes, treatment Croatia [email protected] Received: September 1, 2008 Accepted: January 9, 2009 INTRODUCTION In female body, a vast number of changes oc- bolic imbalances (3), diabetes and cardiovascular cur during pregnancy. Some of them are quite diseases (4). Pregnancy extends and alters the distressing to many women. Therefore, perform- impact of sex differences on absorption, distribu- ing treatment for these changes during pregnancy tion, metabolism and elimination (5). Cardiac out- is discussed. Normal pregnancy needs to avoid put is elevated early and remains elevated for the harmful drugs, both prescribed and over-the coun- remainder of pregnancy. Regional blood flow can ter, and drugs of abuse, including cigarettes, alco- change, with some areas of the skin having sub- hol as well as occupational and environmental ex- stantial increases in blood flow during the course posure to potentially harmful chemicals.
    [Show full text]
  • Abstract #15 Drug Repurposing for Human Visceral Leishmaniasis: Screening Marketed Antifungal Azoles for Inhibition of Leishmani
    Abstract #15 Drug Repurposing for Human Visceral Leishmaniasis: Screening Marketed Antifungal Azoles for Inhibition of Leishmanial CYP5122A1 and CYP51 Enzymes Yiru Jin1, Mei Feng1, Michael Zhuo Wang1 1Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, KS, USA CYP5122A1 is a novel cytochrome P450 (CYP) enzyme that is essential for the survival of Leishmania donovani, a major causative agent for human visceral leishmaniasis. Recent studies suggest that CYP5122A1 plays an important role as sterol 4-demethylase in ergosterol biosynthesis by Leishmania. Thus, CYP5122A1 inhibitors may represent a new therapeutic approach against the devastating infectious disease. To evaluate the effects of antifungal azoles on CYP5122A1, a panel of twenty marketed antifungal azoles (bifonazole, butoconazole, clotrimazole, econazole, efinaconazole, fenticonazole, fluconazole, isavuconazole, isoconazole, itraconazole, ketoconazole, miconazole, oxiconazole, posaconazole, ravuconazole, sertaconazole, sulconazole, terconazole, tioconazole, voriconazole) were screened for inhibition of CYP5122A1, as well as the lanosterol 14α-demethylase CYP51, using a fluorescence-based inhibition assay. All twenty azoles were potent inhibitors of leishmanial CYP51 with IC50 ranging from 0.031 to 0.084 M, whereas their inhibitory potencies against CYP5122A1 were much lower (0.25 to 12 M). Ravuconazole was identified as a selective CYP51 inhibitor with an IC50 value of 0.048 M and selectivity index of 250 against CYP5122A1. Interestingly, the imidazole class of antifungal azoles showed stronger inhibition against CYP5122A1 compared with the triazole class. These results can provide insights toward rational drug design of CYP5122A1 inhibitors. Future studies will attempt to obtain X-ray crystal structures of several select protein-ligand complexes and confirm the proposed biochemical roles of CYP5122A1 and CYP51 by treating parasites with selective inhibitors, followed by HPLC-MS/MS-based sterol analysis.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]